BioSpectrum - Pharma - Suven presents positive phase I data of SUVN-502 ...
Suven Life Sciences presented clinical phase I data for SUVN-502, its 5-HT6 antagonist drug candidate at the 2009 Alzheimer's Association International Conference on ...Suven Life Sciences Ltd Presented Positive Phase-I Clinical Data Of ...
SUVN-502 is a potent, safe, highly selective, brain penetrant and orally active ... The Company targets launching of SUVN-502 in later part of 2013 or early part of ...The Hindu Business Line : SUVN-502 gets DCGI nod for clinical trials
... conduct Phase I clinical trials of SUVN-502, a product used in the ... SUVN-502 is the lead compound, selected from a series of more than 500 compounds, ...SUVN.DE: Summary for SGS N - Yahoo! Finance
Get detailed information on SGS N (SUVN.DE) including quote performance, Real-Time ECN, technical chart analysis, key stats, insider transactions, and the latest ...Suven Life Sciences Initiates Phase I Clinical Trials In Europe Of SUVN ...
Suven Life Sciences Ltd, a Drug Discovery and development company announced at Bio-2008, San Diego that they commenced Phase I clinical trials of SUVN-502, a ...